Shulian Wang
Overview
Explore the profile of Shulian Wang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
89
Citations
1160
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhai Y, Wang L, Zhao H, Wu F, Xin L, Ye F, et al.
JHEP Rep
. 2025 Feb;
7(3):101287.
PMID: 39980754
Background & Aims: Portal and hepatic vein tumor thrombosis is associated with inferior outcomes in patients with hepatocellular carcinoma (HCC), and systemic treatment alone is often insufficient. This phase II...
2.
Ma H, Li H, Xu T, Shi J, Shuai J, Liu S, et al.
Int J Radiat Oncol Biol Phys
. 2025 Jan;
PMID: 39814105
Purpose: To explore differences in the effects of total neoadjuvant therapy (TNT) and preoperative concurrent chemoradiation therapy (CRT) on quality of life and functional outcomes in patients with locally advanced...
3.
Wang S, Li Y, Cai L, Yang X, Pi K, Li Z
Chemosphere
. 2024 Dec;
370():144017.
PMID: 39732406
Cyanobacterial blooms are prevalent globally and present a significant threat to water security. Titanium salt coagulants have garnered considerable attention due to their superior coagulation properties and the absence of...
4.
Xie P, Zhang X, Liu T, Song Y, Zhang Q, Wan D, et al.
Discov Oncol
. 2024 Dec;
15(1):760.
PMID: 39692928
Background: During tumor progression, HER2 expression undergoes dynamic changes. Circulating tumor cells (CTCs) can be used to monitor HER2 expression in real-time and hold potential for clinical application. This study...
5.
Li N, Zhu Y, Liu L, Feng Y, Wang W, Wang J, et al.
Chin J Cancer Res
. 2024 Nov;
36(5):577-586.
PMID: 39539813
Objective: Several studies have been conducted on the effects and toxicity of adding oxaliplatin to fluorouracil-based or capecitabine-based chemoradiotherapy (CRT) regimens as significantly increasing the toxic response without benefit to...
6.
Lu J, Zhou J, Liu Y, Li Y, Tang Y, Li N, et al.
Sci Rep
. 2024 Oct;
14(1):24652.
PMID: 39428391
Small cell carcinoma of the bladder (SCCB) is a rare, highly malignant neuroendocrine tumor. This study attempted to analyze tumor characteristics, treatments and clinical outcomes in China. We conducted a...
7.
Wang J, Liu X, Wu Y, Zhong Q, Wu T, Yang Y, et al.
J Natl Cancer Cent
. 2024 Sep;
4(3):249-259.
PMID: 39281722
Objective: To evaluate whether improved progression-free survival (PFS) from radiotherapy (RT) translates into an overall survival (OS) benefit for diffuse large B-cell lymphoma (DLBCL). Methods: A systematic literature search identified...
8.
Ma H, Li H, Xu T, Gao Y, Liu S, Wang W, et al.
Radiother Oncol
. 2024 Sep;
200:110524.
PMID: 39243864
Purpose: We sought to determine the association between multidisciplinary team (MDT) quality and survival of patients with locally advanced rectal cancer. Methods: In a post hoc analysis of the randomized...
9.
Li Z, Zhai Y, Wu F, Cao D, Ye F, Song Y, et al.
J Hepatocell Carcinoma
. 2024 Aug;
11:1481-1493.
PMID: 39131509
Purpose: This study evaluated the clinical outcomes of patients with hepatocellular carcinoma (HCC) with hepatic vein tumor thrombus (HVTT) and/or inferior vena cava tumor thrombus (IVCTT) receiving radiotherapy (RT) combined...
10.
Gao L, Wei R, Qin S, Tian Y, Xia W, Song Y, et al.
Chronic Dis Transl Med
. 2024 Mar;
10(1):51-61.
PMID: 38450305
Background: Magnetic resonance (MR)-guided ultra-hypofractionated radiotherapy with whole-pelvic irradiation (UHF-WPRT) is a novel approach to radiotherapy for patients with high-risk (HR) and very high-risk (VHR) prostate cancer (PCa). However, the...